查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600911

心臟衰竭药物市场：按治疗、类型、阶段和最终用户分类 - 全球预测 2025-2030

Heart Failure Therapeutics Market by Treatment (Medical Devices, Medicines, Surgery), Type (Diagnosis, Prognosis), Stage, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年心臟衰竭药物市值为239.8亿美元，预计2024年将达到261.6亿美元，复合年增长率为10.46%，到2030年将达到481.3亿美元。

心臟衰竭药物市场包括多种旨在治疗心臟衰竭的治疗方案，心臟衰竭是一种心臟无法泵出足够血液的慢性疾病，影响着全球整体数百万人。该市场包括药品、医疗设备以及基因疗法等创新疗法，旨在缓解症状并提高患者的生活品质。心血管疾病的盛行率不断上升、人口老化以及肥胖和糖尿病等与生活方式相关的危险因子的盛行率不断上升，推动了对心臟衰竭药物的需求。应用范围从急诊医院到慢性门诊医疗护理，最终用途扩展到医院、诊所、门诊医疗中心和居家医疗。关键的成长要素包括诊断和治疗方法的技术进步、正在进行的研究和临床试验以及强大的新药研发管线。此外，政府措施和不断上涨的医疗成本进一步推动了市场成长。新的商机在于个人化医疗和新型药物输送系统的开发，这些系统有望提高疗效和患者依从性。製药公司和研究机构之间的药物发现和开发合作研究也是一个重要机会。然而，市场开拓面临治疗成本高、监管核准严格、药物研发週期长等挑战。此外，来自学名药製造商的竞争可能会阻碍盈利。为了克服这些障碍，该行业应该专注于创新研究，例如识别生物标记、利用人工智慧进行药物发现以及增强以患者为中心的护理模式。市场动态是动态的，竞争与合作并存，永续发展需要对研发进行策略性投资。推动政策改革，采用基于价值的医疗模式并简化核准流程可以促进成长，为医疗保健相关人员提供进入这一不断扩大的领域的机会。

主要市场统计
基准年[2023] 239.8亿美元
预测年份 [2024] 261.6亿美元
预测年份 [2030] 481.3亿美元
复合年增长率（%） 10.46%

市场动态：揭示快速发展的心臟衰竭药物市场的关键市场洞察

供需的动态交互作用正在改变心臟衰竭药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 老年族群心血管疾病盛行率上升
    • 由于生活方式的改变，心臟衰竭和心律不整的敏感性增加
    • 心臟衰竭早期诊断和早期治疗的可能性和偏好
  • 市场限制因素
    • 心臟衰竭治疗的高成本和报销问题
  • 市场机会
    • 心臟衰竭药物的创新与开发
    • 政府的持续努力和私部门投资的增加
  • 市场挑战
    • 对心臟衰竭病症管理的担忧

波特五力：驾驭心臟衰竭药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对心臟衰竭药物市场的影响

外部宏观环境因素在塑造心臟衰竭药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解心臟衰竭治疗药物市场的竞争状况

对心臟衰竭药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV心臟衰竭药物市场定位矩阵供应商绩效评估

FPNV定位矩阵是评估心臟衰竭药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。四个象限清楚且准确地划分了供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 老年族群心血管疾病盛行率上升
      • 生活方式的改变增加了心臟衰竭和心律不整的敏感性
      • 心臟衰竭早期诊断和治疗的可用性和偏好
    • 抑制因素
      • 与心臟衰竭治疗相关的高成本和报销问题
    • 机会
      • 心臟衰竭药物的创新与开发
      • 政府的持续努力和私部门投资的增加
    • 任务
      • 对心臟衰竭病症管理的担忧
  • 市场区隔分析
    • 治疗：消费者越来越多地转向处方药和个人化药物来管理心臟健康
    • 类型：诊断工具和预后创新可以帮助您更好地管理心臟健康
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境
  • 客户客製化

第六章心臟衰竭药物市场：依治疗分类

  • 医疗设备
    • 两级正压空气装置
    • 双心室心律调节器
    • 持续正压呼吸装置
    • 心臟泵
    • 植入式心臟整流去颤器
    • 植入式左心室辅助装置
  • 药品
    • 血管收缩素II受体阻断剂
    • 抗凝血物
    • 抗血小板药
    • 血压维持剂
    • 利尿剂
    • 硝酸盐
    • 他汀类药物
  • 外科手术
    • 心臟再同步
    • 冠状动脉绕道手术手术
    • 冠状动脉重组
    • 心臟移植
    • 心臟瓣膜置换术

第七章心臟衰竭药物市场：依类型

  • 诊断
  • 预后

第八章心臟衰竭药物市场：依阶段

  • A阶段
  • B阶段
  • C阶段
  • D阶段

第九章心臟衰竭药物市场：依最终用户分类

  • 诊所
  • 医院
  • 医学研究所

第十章北美和南美心臟衰竭药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太心臟衰竭药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲心臟衰竭药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
    • FDA 快速核准治疗心臟衰竭的基因治疗药物 AB-1002
    • 诺和诺德收购 Cardiol Pharmaceuticals，透过 RNA 标靶创新扩大心臟衰竭治疗产品组合
    • 美国FDA核准Medtronic心臟病治疗系统
    • 强生将斥资 4 亿美元购买新型心臟植入，以减少中风
    • FDA核准使用带有心臟力调节器的 MRI

公司名单

  • Cardiol Therapeutics Inc.
  • Johnson & Johnson Services, Inc.
  • Verve Therapeutics, Inc.
  • Impulse Dynamics
  • Abbott Laboratories
  • Jarvik Heart, Inc.
  • Berlin Heart GmbH
  • Dr. Reddy's Laboratories Limited
  • Amgen Inc.
  • Glenmark Pharmaceuticals Limited
  • Alembic Pharmaceuticals Limited
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Medtronic PLC
  • Orion Corporation
  • Eli Lilly and Company
  • LivaNova, PLC
  • Cipla Limited
  • Novo Nordisk A/S
  • GlaxoSmithKline PLC
  • AstraZeneca PLC
  • Boston Scientific Corporation
  • Merck & Co., Inc.
  • Beckman Coulter, Inc.
  • Bayer AG
  • Osypka Medical GmbH
  • Biosensors International Group, Ltd.
  • Pfizer, Inc.
  • Biotronik SE & Co. KG
  • Novartis AG
Product Code: MRR-430D42AA0D2E

The Heart Failure Therapeutics Market was valued at USD 23.98 billion in 2023, expected to reach USD 26.16 billion in 2024, and is projected to grow at a CAGR of 10.46%, to USD 48.13 billion by 2030.

The heart failure therapeutics market encompasses a wide range of treatment options aimed at managing heart failure, a chronic condition marked by the heart's inability to pump sufficient blood, which affects millions globally. The scope of this market includes pharmaceuticals, medical devices, and other innovative treatments like gene therapy, designed to alleviate symptoms and improve patient quality of life. The necessity for heart failure therapeutics is driven by the increasing prevalence of cardiovascular diseases, an aging population, and the rising incidence of lifestyle-related risk factors such as obesity and diabetes. Applications range from acute hospital settings to chronic outpatient care, with end-use spread across hospitals, clinics, ambulatory care centers, and home healthcare. Key growth influencers include technological advancements in diagnostic and treatment modalities, ongoing research and clinical trials, and a strong pipeline of new drugs. Moreover, government initiatives and increased healthcare expenditure further augment market growth. Emerging opportunities lie in personalized medicine and the development of novel drug delivery systems, which promise improved efficacy and patient adherence. Collaborations between pharmaceutical companies and research institutions for drug discovery and development are also vital opportunities. However, market growth faces challenges such as high treatment costs, stringent regulatory approvals, and long drug development cycles. Additionally, competition from generic drug manufacturers can hamper profitability. To overcome these barriers, the industry should focus on innovative research in biomarker identification, utilizing artificial intelligence for drug discovery, and enhancing patient-centric care models. The heart failure therapeutics market is dynamic with a blend of competition and collaboration, necessitating strategic investment in R&D for sustained progress. Embracing value-based care models and pushing for policy reforms to streamline approval processes could vitalize growth, offering healthcare stakeholders a chance to tap into this expanding field.

KEY MARKET STATISTICS
Base Year [2023] USD 23.98 billion
Estimated Year [2024] USD 26.16 billion
Forecast Year [2030] USD 48.13 billion
CAGR (%) 10.46%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Heart Failure Therapeutics Market

The Heart Failure Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising Prevalence of Cardiovascular Diseases Among Geriatric Population
    • Growing Susceptibility to Heart Failure and Arrhythmia Owing to Changing Lifestyles
    • Availability and Preferences of Early Diagnosis and Management for Heart Failure
  • Market Restraints
    • High Cost and Reimbursement Issues Related to Heart Failure Treatment
  • Market Opportunities
    • Innovations and Development in the Heart Failure Therapeutics
    • Ongoing Government Initiatives and Increasing Investments by Private Sectors
  • Market Challenges
    • Concerns Related to Management of Heart Failure Condition

Porter's Five Forces: A Strategic Tool for Navigating the Heart Failure Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Heart Failure Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Heart Failure Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Heart Failure Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Heart Failure Therapeutics Market

A detailed market share analysis in the Heart Failure Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Heart Failure Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Heart Failure Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Heart Failure Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Cardiol Therapeutics Inc., Johnson & Johnson Services, Inc., Verve Therapeutics, Inc., Impulse Dynamics, Abbott Laboratories, Jarvik Heart, Inc., Berlin Heart GmbH, Dr. Reddy's Laboratories Limited, Amgen Inc., Glenmark Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Medtronic PLC, Orion Corporation, Eli Lilly and Company, LivaNova, PLC, Cipla Limited, Novo Nordisk A/S, GlaxoSmithKline PLC, AstraZeneca PLC, Boston Scientific Corporation, Merck & Co., Inc., Beckman Coulter, Inc., Bayer AG, Osypka Medical GmbH, Biosensors International Group, Ltd., Pfizer, Inc., Biotronik SE & Co. KG, and Novartis AG.

Market Segmentation & Coverage

This research report categorizes the Heart Failure Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Medical Devices, Medicines, and Surgery. The Medical Devices is further studied across Bi-level positive air pressure device, Biventricular Pacemaker, Continuous Positive Air Pressure Device, Heart Pumps, Implantable Cardioverter-Defibrillators, and Implantable Left Ventricular Assist Device. The Medicines is further studied across Angiotensin II Receptor Blockers, Anticoagulant Medicines, Antiplatelet Medicines, Blood Pressure Maintaining Agents, Diuretics, Nitrates, and Statins. The Surgery is further studied across Cardiac Resynchronization, Coronary Artery Bypass Grafting, Coronary Revascularization, Heart Transplant, and Heart Valve Replacement.
  • Based on Type, market is studied across Diagnosis and Prognosis.
  • Based on Stage, market is studied across Stage A, Stage B, Stage C, and Stage D.
  • Based on End User, market is studied across Clinic, Hospital, and Medical Research Organization.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Prevalence of Cardiovascular Diseases Among Geriatric Population
      • 5.1.1.2. Growing Susceptibility to Heart Failure and Arrhythmia Owing to Changing Lifestyles
      • 5.1.1.3. Availability and Preferences of Early Diagnosis and Management for Heart Failure
    • 5.1.2. Restraints
      • 5.1.2.1. High Cost and Reimbursement Issues Related to Heart Failure Treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations and Development in the Heart Failure Therapeutics
      • 5.1.3.2. Ongoing Government Initiatives and Increasing Investments by Private Sectors
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns Related to Management of Heart Failure Condition
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Extensive consumers shift toward prescribed and personalized medicines for heart health management
    • 5.2.2. Type: Innovations in the diagnostic tools and prognosis helps in better managing the heart health condition
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Heart Failure Therapeutics Market, by Treatment

  • 6.1. Introduction
  • 6.2. Medical Devices
    • 6.2.1. Bi-level positive air pressure device
    • 6.2.2. Biventricular Pacemaker
    • 6.2.3. Continuous Positive Air Pressure Device
    • 6.2.4. Heart Pumps
    • 6.2.5. Implantable Cardioverter-Defibrillators
    • 6.2.6. Implantable Left Ventricular Assist Device
  • 6.3. Medicines
    • 6.3.1. Angiotensin II Receptor Blockers
    • 6.3.2. Anticoagulant Medicines
    • 6.3.3. Antiplatelet Medicines
    • 6.3.4. Blood Pressure Maintaining Agents
    • 6.3.5. Diuretics
    • 6.3.6. Nitrates
    • 6.3.7. Statins
  • 6.4. Surgery
    • 6.4.1. Cardiac Resynchronization
    • 6.4.2. Coronary Artery Bypass Grafting
    • 6.4.3. Coronary Revascularization
    • 6.4.4. Heart Transplant
    • 6.4.5. Heart Valve Replacement

7. Heart Failure Therapeutics Market, by Type

  • 7.1. Introduction
  • 7.2. Diagnosis
  • 7.3. Prognosis

8. Heart Failure Therapeutics Market, by Stage

  • 8.1. Introduction
  • 8.2. Stage A
  • 8.3. Stage B
  • 8.4. Stage C
  • 8.5. Stage D

9. Heart Failure Therapeutics Market, by End User

  • 9.1. Introduction
  • 9.2. Clinic
  • 9.3. Hospital
  • 9.4. Medical Research Organization

10. Americas Heart Failure Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Heart Failure Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Heart Failure Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Grants Fast Track Status to AB-1002 Gene Therapy for Heart Failure
    • 13.3.2. Novo Nordisk to Acquire Cardior Pharmaceuticals, Expanding Heart Failure Therapeutic Portfolio with RNA-Targeted Innovations
    • 13.3.3. US FDA approves Medtronic's system for heart condition
    • 13.3.4. J&J drops USD 400 million to acquire new type of stroke-reducing heart implant
    • 13.3.5. FDA Clears MRI Use with Cardiac Contractility Modulation Device

Companies Mentioned

  • 1. Cardiol Therapeutics Inc.
  • 2. Johnson & Johnson Services, Inc.
  • 3. Verve Therapeutics, Inc.
  • 4. Impulse Dynamics
  • 5. Abbott Laboratories
  • 6. Jarvik Heart, Inc.
  • 7. Berlin Heart GmbH
  • 8. Dr. Reddy's Laboratories Limited
  • 9. Amgen Inc.
  • 10. Glenmark Pharmaceuticals Limited
  • 11. Alembic Pharmaceuticals Limited
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. Bristol-Myers Squibb Company
  • 14. Medtronic PLC
  • 15. Orion Corporation
  • 16. Eli Lilly and Company
  • 17. LivaNova, PLC
  • 18. Cipla Limited
  • 19. Novo Nordisk A/S
  • 20. GlaxoSmithKline PLC
  • 21. AstraZeneca PLC
  • 22. Boston Scientific Corporation
  • 23. Merck & Co., Inc.
  • 24. Beckman Coulter, Inc.
  • 25. Bayer AG
  • 26. Osypka Medical GmbH
  • 27. Biosensors International Group, Ltd.
  • 28. Pfizer, Inc.
  • 29. Biotronik SE & Co. KG
  • 30. Novartis AG

LIST OF FIGURES

  • FIGURE 1. HEART FAILURE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. HEART FAILURE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. HEART FAILURE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. HEART FAILURE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEART FAILURE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEART FAILURE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BI-LEVEL POSITIVE AIR PRESSURE DEVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BIVENTRICULAR PACEMAKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CONTINUOUS POSITIVE AIR PRESSURE DEVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART PUMPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY IMPLANTABLE LEFT VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANT MEDICINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET MEDICINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BLOOD PRESSURE MAINTAINING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY NITRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CARDIAC RESYNCHRONIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CORONARY REVASCULARIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART VALVE REPLACEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE A, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE C, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE D, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL RESEARCH ORGANIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 96. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 98. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 105. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 106. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 112. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 113. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 114. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 119. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 120. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 121. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 126. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 127. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 128. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 130. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 133. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 134. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 135. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 137. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 140. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 141. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 142. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 144. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 147. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 148. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 149. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 151. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 153. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 154. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 155. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 156. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 158. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 160. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 161. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 162. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 163. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 165. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 167. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 168. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 169. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 170. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 172. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. VIETNAM HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. VIETNAM HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 175. VIETNAM HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 176. VIETNAM HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 177. VIETNAM HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. VIETNAM HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 179. VIETNAM HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 188. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 190. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 191. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 192. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 194. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 196. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 197. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 198. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 199. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 201. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 202. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 203. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 204. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 205. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 206. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 208. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 209. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 210. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 211. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 212. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 213. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 215. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 216. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 217. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 218. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 219. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 220. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 222. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 224. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 225. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 226. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 227. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 229. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 232. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 233. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 234. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 236. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 237. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 238. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 239. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 240. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 241. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 243. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 244. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 245. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 246. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 247. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 248. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 250. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 251. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 252. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 253. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 254. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 255. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 257. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 258. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 259. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 260. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 261. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 262. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 264. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 265. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 266. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 267. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 268. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 269. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 271. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 273. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 274. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 275. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 276. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 278. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 279. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 280. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 281. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 282. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 283. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 285. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 286. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 287. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 288. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 289. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 290. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 292. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 293. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 294. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 295. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 296. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 297. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 299. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 300. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 301. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 302. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 303. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 304. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 306. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 307. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 308. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 309. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 310. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 311. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 313. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 314. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 315. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 316. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 317. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 318. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 319. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 320. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 327. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 328. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 329. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 330. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 331. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 332. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)

TAB